{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:04:40Z","timestamp":1793689480704,"version":"4.5.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07385-3","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:43:27Z","timestamp":1764938607000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Research progress in molecular targeted therapy for inflammatory bowel disease"],"prefix":"10.1186","volume":"24","author":[{"given":"Nan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengye","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lishuai","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"7385_CR1","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1016\/j.cgh.2023.08.013","volume":"21","author":"L Xu","year":"2023","unstructured":"Xu L, et al. Incidence of inflammatory bowel disease in urban china: A nationwide Population-based study. Clin Gastroenterol Hepatol. 2023;21:3379\u2013e33863329.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7385_CR2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1146\/annurev.med.60.051407.123757","volume":"60","author":"C Abraham","year":"2009","unstructured":"Abraham C, Cho JH. IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2009;60:97\u2013110.","journal-title":"Annu Rev Med"},{"key":"7385_CR3","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1053\/j.gastro.2016.10.018","volume":"152","author":"C Abraham","year":"2017","unstructured":"Abraham C, et al. Lessons learned from trials targeting cytokine pathways in patients with inflammatory bowel diseases. Gastroenterology. 2017;152:374\u2013e388374.","journal-title":"Gastroenterology"},{"key":"7385_CR4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/j.1365-2796.2008.01953.x","volume":"263","author":"I Atreya","year":"2008","unstructured":"Atreya I, Atreya R, Neurath MF. NF-kappaB in inflammatory bowel disease. J Intern Med. 2008;263:591\u20136.","journal-title":"J Intern Med"},{"key":"7385_CR5","doi-asserted-by":"publisher","first-page":"117390","DOI":"10.1016\/j.biopha.2024.117390","volume":"179","author":"Y Pourmehran","year":"2024","unstructured":"Pourmehran Y, et al. Exploring the influence of non-coding RNAs on NF-\u03baB signaling pathway regulation in ulcerative colitis. Biomed Pharmacother. 2024;179:117390.","journal-title":"Biomed Pharmacother"},{"key":"7385_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.tips.2016.10.014","volume":"38","author":"M Coskun","year":"2017","unstructured":"Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci. 2017;38:127\u201342.","journal-title":"Trends Pharmacol Sci"},{"key":"7385_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","volume":"117","author":"D Tracey","year":"2008","unstructured":"Tracey D, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244\u201379.","journal-title":"Pharmacol Ther"},{"key":"7385_CR8","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1002\/art.23436","volume":"58","author":"C Skhirtladze","year":"2008","unstructured":"Skhirtladze C, et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum. 2008;58:1475\u201384.","journal-title":"Arthritis Rheum"},{"key":"7385_CR9","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","volume":"124","author":"JM Van den Brande","year":"2003","unstructured":"Van den Brande JM, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with crohn\u2019s disease. Gastroenterology. 2003;124:1774\u201385.","journal-title":"Gastroenterology"},{"key":"7385_CR10","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s11096-018-0743-4","volume":"40","author":"C Trigo-Vicente","year":"2018","unstructured":"Trigo-Vicente C, et al. Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis. Int J Clin Pharm. 2018;40:1411\u20139.","journal-title":"Int J Clin Pharm"},{"key":"7385_CR11","doi-asserted-by":"publisher","first-page":"828219","DOI":"10.3389\/fimmu.2022.828219","volume":"13","author":"B Yu","year":"2022","unstructured":"Yu B, et al. Model-Based Meta-Analysis on the efficacy of biologics and small targeted molecules for crohn\u2019s disease. Front Immunol. 2022;13:828219.","journal-title":"Front Immunol"},{"key":"7385_CR12","doi-asserted-by":"publisher","first-page":"903677","DOI":"10.3389\/fped.2022.903677","volume":"10","author":"M Cla\u00dfen","year":"2022","unstructured":"Cla\u00dfen M, et al. Significant advantages for first line treatment with TNF-alpha inhibitors in pediatric patients with inflammatory bowel disease - Data from the multicenter CEDATA-GPGE registry study. Front Pediatr. 2022;10:903677.","journal-title":"Front Pediatr"},{"key":"7385_CR13","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1038\/ctg.2016.49","volume":"7","author":"CR Heier","year":"2016","unstructured":"Heier CR, et al. Identification of Pathway-Specific serum biomarkers of response to glucocorticoid and Infliximab treatment in children with inflammatory bowel disease. Clin Transl Gastroenterol. 2016;7:e192.","journal-title":"Clin Transl Gastroenterol"},{"key":"7385_CR14","doi-asserted-by":"crossref","unstructured":"Andersen V, Hansen AK, Heitmann BL. Potential impact of diet on treatment effect from anti-TNF drugs in inflammatory bowel disease. Nutrients. 2017;9.","DOI":"10.20944\/preprints201703.0093.v1"},{"key":"7385_CR15","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/1751-2980.13026","volume":"22","author":"L Chen","year":"2021","unstructured":"Chen L, et al. Anti-TNF and immunosuppressive combination therapy is Preferential to inducing clinical remission in patients with active inflammatory bowel disease: A systemic review and meta-analysis. J Dig Dis. 2021;22:408\u201318.","journal-title":"J Dig Dis"},{"key":"7385_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s12664-020-01031-0","volume":"39","author":"BS Dhindsa","year":"2020","unstructured":"Dhindsa BS, et al. Reversal of anti-drug antibodies against tumor necrosis factor inhibitors with addition of immunomodulators: A systematic review and meta-analysis. Indian J Gastroenterol. 2020;39:153\u201360.","journal-title":"Indian J Gastroenterol"},{"key":"7385_CR17","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/apt.13083","volume":"41","author":"JP Gisbert","year":"2015","unstructured":"Gisbert JP, et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41:613\u201323.","journal-title":"Aliment Pharmacol Ther"},{"key":"7385_CR18","doi-asserted-by":"publisher","first-page":"115080","DOI":"10.1016\/j.addr.2023.115080","volume":"201","author":"V Andretto","year":"2023","unstructured":"Andretto V, et al. Tackling TNF-\u03b1 in autoinflammatory disorders and autoimmune diseases: from conventional to cutting edge in biologics and RNA- based nanomedicines. Adv Drug Deliv Rev. 2023;201:115080.","journal-title":"Adv Drug Deliv Rev"},{"key":"7385_CR19","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1056\/NEJMoa054693","volume":"354","author":"TA Yousry","year":"2006","unstructured":"Yousry TA, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med. 2006;354:924\u201333.","journal-title":"N Engl J Med"},{"key":"7385_CR20","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","volume":"366","author":"G Bloomgren","year":"2012","unstructured":"Bloomgren G, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366:1870\u201380.","journal-title":"N Engl J Med"},{"key":"7385_CR21","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369:699\u2013710.","journal-title":"N Engl J Med"},{"key":"7385_CR22","doi-asserted-by":"publisher","first-page":"e30590","DOI":"10.1097\/MD.0000000000030590","volume":"101","author":"B Qiu","year":"2022","unstructured":"Qiu B, Liang JX, Li C. Efficacy and safety of Vedolizumab for inflammatory bowel diseases: A systematic review and meta-analysis of randomized controlled trials. Med (Baltim). 2022;101:e30590.","journal-title":"Med (Baltim)"},{"key":"7385_CR23","doi-asserted-by":"publisher","first-page":"100381","DOI":"10.1016\/j.xcrm.2021.100381","volume":"2","author":"B Dai","year":"2021","unstructured":"Dai B, et al. Dual targeting of lymphocyte homing and retention through \u03b14\u03b27 and \u03b1E\u03b27 Inhibition in inflammatory bowel disease. Cell Rep Med. 2021;2:100381.","journal-title":"Cell Rep Med"},{"key":"7385_CR24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2468-1253(21)00298-3","volume":"7","author":"L Peyrin-Biroulet","year":"2022","unstructured":"Peyrin-Biroulet L, et al. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2022;7:128\u201340.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"7385_CR25","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.4049\/jimmunol.2100220","volume":"207","author":"ME Keir","year":"2021","unstructured":"Keir ME, et al. Regulation and role of \u03b1E integrin and gut homing integrins in migration and retention of intestinal lymphocytes during inflammatory bowel disease. J Immunol. 2021;207:2245\u201354.","journal-title":"J Immunol"},{"key":"7385_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.pharmthera.2014.11.008","volume":"147","author":"I Mitroulis","year":"2015","unstructured":"Mitroulis I, et al. Role in leukocyte recruitment and as therapeutic targets in inflammatory disease. Pharmacol Ther. 2015;147:123\u201335.","journal-title":"Pharmacol Ther"},{"key":"7385_CR27","first-page":"106","volume":"48","author":"J Lasa","year":"2018","unstructured":"Lasa J, Rausch A, Zubiaurre I. Efficacy and safety of anti-integrin antibodies in inflammatory bowel disease: systematic review and meta-analysis. Acta Gastroenterol\u00f3gica Latinoam. 2018;48:106\u201316.","journal-title":"Acta Gastroenterol\u00f3gica Latinoam"},{"key":"7385_CR28","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1007\/s00535-018-1480-0","volume":"53","author":"S Schreiber","year":"2018","unstructured":"Schreiber S, et al. Systematic review with meta-analysis: real-world effectiveness and safety of Vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018;53:1048\u201364.","journal-title":"J Gastroenterol"},{"key":"7385_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/apt.15294","volume":"50","author":"A Amiot","year":"2019","unstructured":"Amiot A, et al. Three-year effectiveness and safety of Vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study. Aliment Pharmacol Ther. 2019;50:40\u201353.","journal-title":"Aliment Pharmacol Ther"},{"key":"7385_CR30","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1111\/apt.15484","volume":"50","author":"S Singh","year":"2019","unstructured":"Singh S, et al. Systematic review with meta-analysis: association between Vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2019;50:848\u201357.","journal-title":"Aliment Pharmacol Ther"},{"key":"7385_CR31","doi-asserted-by":"publisher","first-page":"e688","DOI":"10.14309\/01.ajg.0000860460.33213.97","volume":"117","author":"P Santiago","year":"2022","unstructured":"Santiago P, et al. S955\u2003Effectiveness of Vedolizumab in patients with inflammatory bowel disease and concomitant primary sclerosing cholangitis. Official J Am Coll Gastroenterol | ACG. 2022;117:e688\u20139.","journal-title":"Official J Am Coll Gastroenterol | ACG"},{"key":"7385_CR32","doi-asserted-by":"publisher","first-page":"i195","DOI":"10.1093\/ecco-jcc\/jjac190.0155","volume":"17","author":"E Csomor","year":"2023","unstructured":"Csomor E, et al. P025 colonic rather than ileal expression of ITGA4\/ITGB7 correlates with local intestinal inflammation in IBD. J Crohn\u2019s Colitis. 2023;17:i195\u20136.","journal-title":"J Crohn\u2019s Colitis"},{"key":"7385_CR33","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1136\/annrheumdis-2016-210233","volume":"76","author":"G Varkas","year":"2017","unstructured":"Varkas G, et al. An induction or flare of arthritis and\/or sacroiliitis by Vedolizumab in inflammatory bowel disease: a case series. Ann Rheum Dis. 2017;76:878\u201381.","journal-title":"Ann Rheum Dis"},{"key":"7385_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2013.06.007","volume":"76","author":"M Coskun","year":"2013","unstructured":"Coskun M, et al. Involvement of JAK\/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res. 2013;76:1\u20138.","journal-title":"Pharmacol Res"},{"key":"7385_CR35","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.tips.2022.02.008","volume":"43","author":"OH Nielsen","year":"2022","unstructured":"Nielsen OH, et al. Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease. Trends Pharmacol Sci. 2022;43:424\u201336.","journal-title":"Trends Pharmacol Sci"},{"key":"7385_CR36","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"WJ Sandborn","year":"2017","unstructured":"Sandborn WJ, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723\u201336.","journal-title":"N Engl J Med"},{"key":"7385_CR37","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","volume":"66","author":"J Pan\u00e9s","year":"2017","unstructured":"Pan\u00e9s J, et al. Tofacitinib for induction and maintenance therapy of crohn\u2019s disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017;66:1049\u201359.","journal-title":"Gut"},{"key":"7385_CR38","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","volume":"389","author":"S Vermeire","year":"2017","unstructured":"Vermeire S, et al. Clinical remission in patients with moderate-to-severe crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389:266\u201375.","journal-title":"Lancet"},{"key":"7385_CR39","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, et al. Efficacy and safety of Upadacitinib in a randomized trial of patients with crohn\u2019s disease. Gastroenterology. 2020;158:2123\u2013e21382128.","journal-title":"Gastroenterology"},{"key":"7385_CR40","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1093\/ecco-jcc\/jjad100","volume":"17","author":"V Solitano","year":"2023","unstructured":"Solitano V, et al. Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: systematic review and Meta-Analysis. J Crohns Colitis. 2023;17:1800\u201316.","journal-title":"J Crohns Colitis"},{"key":"7385_CR41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/apt.15297","volume":"50","author":"C Ma","year":"2019","unstructured":"Ma C, et al. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Aliment Pharmacol Ther. 2019;50:5\u201323.","journal-title":"Aliment Pharmacol Ther"},{"key":"7385_CR42","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1177\/2050640620942641","volume":"8","author":"VB Biemans","year":"2020","unstructured":"Biemans VB, Verstockt B. Tofacitinib, two-faced Janus in ulcerative colitis and crohn\u2019s disease? United Eur Gastroenterol J. 2020;8:753\u20134.","journal-title":"United Eur Gastroenterol J"},{"key":"7385_CR43","doi-asserted-by":"publisher","first-page":"S746","DOI":"10.1093\/ecco-jcc\/jjz186","volume":"14","author":"G Rogler","year":"2020","unstructured":"Rogler G. Efficacy of JAK inhibitors in crohn\u2019s disease. J Crohns Colitis. 2020;14:S746\u201354.","journal-title":"J Crohns Colitis"},{"key":"7385_CR44","doi-asserted-by":"publisher","first-page":"S238","DOI":"10.1093\/ecco-jcc\/jjx180.400","volume":"12","author":"J Panes","year":"2018","unstructured":"Panes J, et al. P273 efficacy and safety of Upadacitinib maintenance treatment for moderate to severe crohn\u2019s disease: results from the CELEST study. J Crohn\u2019s Colitis. 2018;12:S238\u20139.","journal-title":"J Crohn\u2019s Colitis"},{"key":"7385_CR45","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1053\/j.gastro.2004.01.012","volume":"126","author":"H Ito","year":"2004","unstructured":"Ito H, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active crohn\u2019s disease. Gastroenterology. 2004;126:989\u201396. discussion 947.","journal-title":"Gastroenterology"},{"key":"7385_CR46","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.pharmthera.2013.09.004","volume":"141","author":"X Yao","year":"2014","unstructured":"Yao X, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2014;141:125\u201339.","journal-title":"Pharmacol Ther"},{"key":"7385_CR47","doi-asserted-by":"publisher","first-page":"i028","DOI":"10.1093\/ecco-jcc\/jjab232.025","volume":"16","author":"G D\u2019Haens","year":"2022","unstructured":"D\u2019Haens G, et al. OP26 efficacy and safety of Mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 LUCENT-1 study. J Crohn\u2019s Colitis. 2022;16:i028\u20139.","journal-title":"J Crohn\u2019s Colitis"},{"key":"7385_CR48","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nm.3895","volume":"21","author":"MW Teng","year":"2015","unstructured":"Teng MW, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015;21:719\u201329.","journal-title":"Nat Med"},{"key":"7385_CR49","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/ng.733","volume":"43","author":"Y Momozawa","year":"2011","unstructured":"Momozawa Y, et al. Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. Nat Genet. 2011;43:43\u20137.","journal-title":"Nat Genet"},{"key":"7385_CR50","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.4049\/jimmunol.168.11.5699","volume":"168","author":"C Parham","year":"2002","unstructured":"Parham C, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168:5699\u2013708.","journal-title":"J Immunol"},{"key":"7385_CR51","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/apt.16802","volume":"55","author":"H Yang","year":"2022","unstructured":"Yang H, et al. Systematic review with meta-analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases. Aliment Pharmacol Ther. 2022;55:764\u201377.","journal-title":"Aliment Pharmacol Ther"},{"key":"7385_CR52","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s12328-020-01242-0","volume":"14","author":"K Murate","year":"2021","unstructured":"Murate K, et al. Ustekinumab is effective against small bowel lesions in crohn\u2019s disease: two case reports. Clin J Gastroenterol. 2021;14:129\u201335.","journal-title":"Clin J Gastroenterol"},{"key":"7385_CR53","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1620\/tjem.255.57","volume":"255","author":"Y Fujita","year":"2021","unstructured":"Fujita Y, et al. Ustekinumab as the first biological agent for crohn\u2019s disease in a 10-Year-Old Girl. Tohoku J Exp Med. 2021;255:57\u201360.","journal-title":"Tohoku J Exp Med"},{"key":"7385_CR54","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.molmed.2017.02.002","volume":"23","author":"OH Nielsen","year":"2017","unstructured":"Nielsen OH, et al. Sphingosine-1-Phosphate signaling in inflammatory bowel disease. Trends Mol Med. 2017;23:362\u201374.","journal-title":"Trends Mol Med"},{"key":"7385_CR55","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1093\/ecco-jcc\/jjad162","volume":"18","author":"R Atreya","year":"2024","unstructured":"Atreya R, et al. Submucosal injection of the RNA oligonucleotide GUT-1 in active ulcerative colitis patients: A Randomized, Double-Blind, Placebo-Controlled phase 2a induction trial. J Crohns Colitis. 2024;18:406\u201315.","journal-title":"J Crohns Colitis"},{"key":"7385_CR56","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1053\/j.gastro.2021.06.015","volume":"161","author":"L Peyrin-Biroulet","year":"2021","unstructured":"Peyrin-Biroulet L, et al. Histologic outcomes with Vedolizumab versus adalimumab in ulcerative colitis: results from an efficacy and safety study of Vedolizumab intravenous compared to adalimumab subcutaneous in participants with ulcerative colitis (VARSITY). Gastroenterology. 2021;161:1156\u2013e11671153.","journal-title":"Gastroenterology"},{"key":"7385_CR57","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.cgh.2021.12.030","volume":"20","author":"G D\u2019Haens","year":"2022","unstructured":"D\u2019Haens G, et al. Upadacitinib was efficacious and Well-tolerated over 30 months in patients with crohn\u2019s disease in the CELEST extension study. Clin Gastroenterol Hepatol. 2022;20:2337\u2013e23462333.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7385_CR58","doi-asserted-by":"publisher","first-page":"i1811","DOI":"10.1093\/ecco-jcc\/jjad212.1128","volume":"18","author":"W Reinisch","year":"2024","unstructured":"Reinisch W, et al. P998 phase 2 basket design study evaluating the efficacy and safety of an anti-TL1A antibody (TEV-48574) in moderate to severe ulcerative colitis or crohn\u2019s disease (RELIEVE UCCD). J Crohn\u2019s Colitis. 2024;18:i1811\u20131811.","journal-title":"J Crohn\u2019s Colitis"},{"key":"7385_CR59","doi-asserted-by":"publisher","first-page":"i042","DOI":"10.1093\/ecco-jcc\/jjab232.035","volume":"16","author":"BE Sands","year":"2022","unstructured":"Sands BE, et al. OP36 efficacy and safety of combination induction therapy with Guselkumab and golimumab in participants with moderately-to-severely active ulcerative colitis: results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study. J Crohn\u2019s Colitis. 2022;16:i042\u20133.","journal-title":"J Crohn\u2019s Colitis"},{"key":"7385_CR60","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/apt.17557","volume":"58","author":"G D\u2019Haens","year":"2023","unstructured":"D\u2019Haens G, et al. A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis. Aliment Pharmacol Ther. 2023;58:283\u201396.","journal-title":"Aliment Pharmacol Ther"},{"key":"7385_CR61","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/apt.14852","volume":"48","author":"S Singh","year":"2018","unstructured":"Singh S, et al. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn\u2019s disease. Aliment Pharmacol Ther. 2018;48:394\u2013409.","journal-title":"Aliment Pharmacol Ther"},{"key":"7385_CR62","doi-asserted-by":"crossref","unstructured":"Hindryckx P, et al. Biologic drugs for induction and maintenance of remission in Crohn\u2019s disease: a network meta\u2010analysis. Cochrane Db Syst Rev. 2017;8:1465\u2013858. https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD012751\/full","DOI":"10.1002\/14651858.CD012751"},{"key":"7385_CR63","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1111\/apt.16005","volume":"52","author":"D Laharie","year":"2020","unstructured":"Laharie D, Riviere P. Editorial: biologics in the therapy of crohn\u2019s disease-the fog clears. Aliment Pharmacol Ther. 2020;52:1214\u20135.","journal-title":"Aliment Pharmacol Ther"},{"key":"7385_CR64","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1007\/s10620-023-07837-0","volume":"68","author":"EM Berinstein","year":"2023","unstructured":"Berinstein EM, et al. Efficacy and safety of dual targeted therapy for partially or non-responsive inflammatory bowel disease: a systematic review of the literature. Dig Dis Sci. 2023;68:2604\u201323.","journal-title":"Dig Dis Sci"},{"key":"7385_CR65","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1080\/1744666X.2022.2104713","volume":"18","author":"F D\u2019Amico","year":"2022","unstructured":"D\u2019Amico F, Danese S, Fiorino G. Could small molecules be used in combination with biologics for inflammatory bowel disease? Expert Rev Clin Immunol. 2022;18:991\u20133.","journal-title":"Expert Rev Clin Immunol"},{"key":"7385_CR66","doi-asserted-by":"crossref","unstructured":"Kellar, A., et al. Real-world outcomes of dual advanced therapy in children and young adults with inflammatory bowel disease. Dig Dis Sci. 2024;69:1826\u201333. https:\/\/pubmed.ncbi.nlm.nih.gov\/38521850\/","DOI":"10.1007\/s10620-024-08379-9"},{"key":"7385_CR67","doi-asserted-by":"crossref","unstructured":"Rodrigues Junior JI, et al. Antioxidant therapy in inflammatory bowel disease: a systematic review and a meta-analysis of randomized clinical trials. Pharmaceuticals (Basel). 2023;16.","DOI":"10.3390\/ph16101374"},{"key":"7385_CR68","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa043335","volume":"353","author":"WJ Sandborn","year":"2005","unstructured":"Sandborn WJ, et al. Natalizumab induction and maintenance therapy for crohn\u2019s disease. N Engl J Med. 2005;353:1912\u201325.","journal-title":"N Engl J Med"},{"key":"7385_CR69","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","volume":"385","author":"WJ Sandborn","year":"2021","unstructured":"Sandborn WJ, et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021;385:1280\u201391.","journal-title":"N Engl J Med"},{"key":"7385_CR70","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, et al. Cardiovascular and cancer risk with Tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u201326.","journal-title":"N Engl J Med"},{"key":"7385_CR71","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","volume":"8","author":"BG Feagan","year":"2023","unstructured":"Feagan BG, et al. Guselkumab plus golimumab combination therapy versus Guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol. 2023;8:307\u201320.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"7385_CR72","doi-asserted-by":"publisher","first-page":"e70198","DOI":"10.1111\/cts.70198","volume":"18","author":"F Yin","year":"2025","unstructured":"Yin F, et al. Comparative effectiveness of dual biologic therapy and biologic Small-Molecule therapy for refractory inflammatory bowel disease: A retrospective Single-Center study. Clin Transl Sci. 2025;18:e70198.","journal-title":"Clin Transl Sci"},{"key":"7385_CR73","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.cgh.2020.04.078","volume":"19","author":"N Vande Casteele","year":"2021","unstructured":"Vande Casteele N, et al. Development and validation of a clinical decision support tool that incorporates Pharmacokinetic data to predict endoscopic healing in patients treated with Infliximab. Clin Gastroenterol Hepatol. 2021;19:1209\u2013e12171202.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7385_CR74","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41746-025-01627-w","volume":"8","author":"VA Rudrapatna","year":"2025","unstructured":"Rudrapatna VA, et al. From trial data to personalized medicine: a validated framework with an application to crohn\u2019s disease. NPJ Digit Med. 2025;8:327.","journal-title":"NPJ Digit Med"},{"key":"7385_CR75","doi-asserted-by":"publisher","unstructured":"Cervera Seco L, et al. P897 longitudinal multi-tissue transcriptomic study reveals patient-specific drug response determinants in inflammatory bowel disease patients. J Crohns Colitis. 2023;17:i1011. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjac190.1027","DOI":"10.1093\/ecco-jcc\/jjac190.1027"},{"key":"7385_CR76","doi-asserted-by":"publisher","first-page":"13507","DOI":"10.1038\/ncomms13507","volume":"7","author":"NT Ventham","year":"2016","unstructured":"Ventham NT, et al. Integrative epigenome-wide analysis demonstrates that DNA methylation May mediate genetic risk in inflammatory bowel disease. Nat Commun. 2016;7:13507.","journal-title":"Nat Commun"},{"key":"7385_CR77","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nm.4307","volume":"23","author":"NR West","year":"2017","unstructured":"West NR, et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat Med. 2017;23:579\u201389.","journal-title":"Nat Med"},{"key":"7385_CR78","doi-asserted-by":"crossref","unstructured":"Hani\u0107 M, et al. Anti-TNF biologicals enhance the anti-inflammatory properties of IgG N-glycome in Crohn\u2019s disease. Biomolecules. 2023;13.","DOI":"10.3390\/biom13060954"},{"key":"7385_CR79","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/s41586-019-1237-9","volume":"569","author":"J Lloyd-Price","year":"2019","unstructured":"Lloyd-Price J, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019;569:655\u201362.","journal-title":"Nature"},{"key":"7385_CR80","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/cts.12850","volume":"14","author":"KV Rogers","year":"2021","unstructured":"Rogers KV, et al. A dynamic quantitative systems Pharmacology model of inflammatory bowel disease: part 2 - Application to current therapies in crohn\u2019s disease. Clin Transl Sci. 2021;14:249\u201359.","journal-title":"Clin Transl Sci"},{"key":"7385_CR81","doi-asserted-by":"publisher","first-page":"i1011","DOI":"10.1093\/ecco-jcc\/jjac190.1027","volume":"17","author":"L Cervera Seco","year":"2023","unstructured":"Cervera Seco L, et al. P897 longitudinal multi-tissue transcriptomic study reveals patient-specific drug response determinants in inflammatory bowel disease patients. J Crohn\u2019s Colitis. 2023;17:i1011\u20131011.","journal-title":"J Crohn\u2019s Colitis"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07385-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07385-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07385-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:32:29Z","timestamp":1768473149000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-07385-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7385"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07385-3","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All uses of the images in this article have obtained permission from the publishers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Approval of the research protocol by an institutional reviewer board"}},{"value":"N\/A","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal studies"}},{"value":"N\/A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"N\/A.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Registry and the registration no. of the study\/trial"}},{"value":"The authors declare that they have no competing interests.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}